🇺🇸 FDA
Patent

US 11202822

Methods for treating hypophosphatemic disorders

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11202822 (Methods for treating hypophosphatemic disorders) held by Ultragenyx Pharmaceutical Inc. expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ultragenyx Pharmaceutical Inc.
Grant date
Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/001132